With the grant of 2.5 MEUR from the European Innovation Council (EIC) Accelerator Program, Elicera is now fully funded to complete a clinical phase I/II to evaluate its CAR T-cell ELC-301 therapy for the treatment of B-cell lymphoma. fierce competition (only 5% of applications are approved) and provides validation of Elicera’s science and research. corresponding to a SEK1.3 per action, the grant also frees up resources for other projects in the portfolio. Therefore, we now find support for a fair value of 13 (12) SEK per share in 12 to 24 months.

2.5 MEUR funding for ELC-301
Elicera is a clinical-stage cell and gene therapy company developing immuno-oncology therapies focused on CART-enhanced T cells and oncolytic viruses. Elicera now believes that the planned phase I/II clinical development of the CAR T-cell ELC-301 therapy will be fully funded, having obtained 26 MSEK from the European Innovation Council (EIC) Acceleration program. With this grant, the company has now secured a total of 40 MSEK for the ELC-301 program, which is expected to enter clinical phase I/II in H2’22. The EIC-accelerator program provides funding support and accelerator services for small and medium-sized enterprises with an approval rate of less than five percent, which is why we believe the grant provides tremendous validation for science. and looking for Elicera.

Elicera armed with a broad product portfolio
The approved CAR T-cell therapies available today target the CD19 protein and although these have been shown to be effective, a large proportion of patients are either resistant to treatment or relapse within twelve months. These patients then often lost the CD19 target antigen on recurrent tumors. ELC-301, which is the fourth generation CAR T cell therapy, instead targets the CD20 protein, which is expressed on all B-cell lymphoma cells. ELC-301 is also armed with platform iTANK technology Elicera CAR T Cell Amplifier that delivers a broader attack on cancer by also activating the patient’s own T cells against all of the relevant target antigens on tumor cells, not just CD19 or CD20. In addition to ELC-301 and ELC-100, Elicera has two additional drug candidates in its pipeline, ELC-201 and ELC-401, both in the preclinical phase.

A stable pipeline of triggers supports revaluation potential
For Elicera’s other project, ELC-100, an oncolytic virus for the treatment of neuroendocrine tumors, we now look forward to efficacy data from the ongoing Phase I/II study in 2022. With a portfolio of immuno-oncology projects in the clinical and preclinical phases, as well as the iTANK platform which is already in the commercial phase, and a stable pipeline of triggers during the year, more SEK1.3 per share in the EIC grants for the next phase I/II with ELC-301, we find broad support for a revaluation of the share. The company’s strategy is focused on partnerships after the initial clinical phases and with effective measures and potential for early licensing of ELC-100, the start of clinical studies for ELC-301 and probable pilot agreements for iTANK in 2022 we see an overall risk – adjusted net present value for these three verticals at 256 MSEK or a fair value of 13 (12) SEK per share.

Read the full Elicera report here: https://www.emergers.se/elicera_h/